CLRBD Stock UPDATES Cellectar Biosciences Inc. (CLRBD) 6.7400

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellectar Biosciences Inc. (CLRBD) 6.7400 $CLRBD

Cellectar Biosciences to Host Conference Call on August 20th to Discuss Second Quarter 2014 Results and Provide Quarterly Update on Development Progress
GlobeNewswire - Mon Aug 18, 3:15PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss second quarter 2014 financial results and provide an update on each of its development programs on Wednesday, August 20th at 5:00 PM ET.

OTC Markets Group Congratulates Cellectar Biosciences on NASDAQ Listing
PR Newswire - Fri Aug 15, 8:29AM CDT
OTC Markets Group Inc. (OTCQX: OTCM) congratulates Cellectar Biosciences Inc., on its successful public offering and approval to list on The NASDAQ Capital Market, effective August 15, 2014. Cellectar previously traded on OTCQX®, the best marketplace for established U.S. and global companies operated by OTC Markets Group.

Cellectar Biosciences Announces Pricing of $12,500,000 Public Offering and Listing on The Nasdaq Capital Market
GlobeNewswire - Thu Aug 14, 6:40PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced today the pricing of an underwritten public offering of 3,333,333 shares of its common stock at a per share price of $3.75 and warrants to purchase up to the same number of shares of common stock at a per warrant price of $0.01; plus the issuance of approximately an additional 1,110,000 shares and warrants in consideration of the cancellation of $4,000,000 principal amount of convertible debentures plus accrued interest. The warrants are exercisable immediately and expire five years from their date of issuance. The warrants will have an exercise price of $4.68 per share and will trade on the NASDAQ Capital Market under the symbol "CLRBW."

Cellectar Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed/refractory multiple myeloma, an incurable cancer of plasma cells.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Immunofoco’s Lentiviral Strategy for Cancer Control

Updated Category News Views 109

Revolutionizing Cancer Treatment: Immunofoco's Approach In the battle against B-cell malignancies, the old ways of doing things sometimes just don’t cut it, folks. Enter Immunofoco. At the recent Society for Immunotherapy of Cancer (SITC) 2026 meeting, they laid some ambitious cards on the table with their in vivo T-cell engager (TCE) delivery strategy. Engineering...

Continue Reading
AppLovin Faces Class Action as Promises Fall Short

Updated Category News Views 65

Class Action Shadows AppLovin Over AI Promises What a tangled web AppLovin has woven for itself. Promises of rapid AI advancements and a slick video tool rollout seemed like a done deal back in the early months of 2026. Well, that was until the cracks started to show by August. Promises Made, Promises Broken The saga kicked off on May 6, 2026, with AppLovin's confident...

Continue Reading
Johnine Barnes Joins Prestigious Labor & Employment Fellowship

Updated Category News Views 88

A Nod to Legal Excellence In the world of labor and employment law, notches on the belt come from more than just winning cases. It's about mastering the balance between legal prowess and professional grace—a cocktail that Johnine P. Barnes seems to have perfected. Just this November, Barnes was elected as a fellow of the College of Labor & Employment Lawyers (CLEL), a...

Continue Reading
Claus for a Cause: Respecting Heroes with Holiday Cheer

Updated Category News Views 100

An Unforgettable Holiday Season Veterans Day isn't just a date on the calendar—it's an opportunity to pause and offer genuine thanks to those who've served with honor. This year, as the holiday season rolls around, Gemmy Industries' Claus for a Cause collection is redefining how we show our appreciation. These aren't your ordinary inflatables; they come with a purpose...

Continue Reading
Silicosis Crisis: Legal and Health Ramifications Loom

Updated Category News Views 58

The Hidden Dangers of Artificial Stone Here's the grim truth. Artificial stone countertops, loved by many for their aesthetics in kitchens and bathrooms, have a dark side that’s becoming increasingly hard to ignore. Loaded with more than 90% respirable crystalline silica, these materials spew out toxic dust when cut or polished. Once that dust gets airborne, workers...

Continue Reading
Strauss Group Preps Q3 2026 Earnings Release, Webinar

Updated Category News Views 50

Earnings Are Around the Corner for Strauss Group This thing's been coming down the pipeline, and now it's official: Strauss Group Ltd. (TASE: STRS) is throwing open the curtain on its third quarter numbers come November 25, 2026. Mark the date, folks: it's a Wednesday. And in this game, timings matter a heap more than you'd think. With the financial world constantly...

Continue Reading
Huairen Ceramics: Tech Upgrade Powers Global Aspirations

Updated Category News Views 100

Tech Revolution in Porcelain's Traditional Hearth Imagine robots glazing porcelain and kilns all on autopilot—that's the new norm at Huairen City, Shanxi Province, home to China's formidable porcelain industry. Gone are the days when craftsmen relied solely on their keen senses to judge the right glaze and firing time. The latest technology has disrupted tradition here,...

Continue Reading
Fluence Energy Lawsuit: Investor Unrest Unleashed

Updated Category News Views 112

The Turbulence Behind FLNC: A Hard Pill to Swallow Looks like Fluence Energy (NASDAQ: FLNC) has stumbled right into a mess that's leaving investors with a bitter aftertaste. A securities class action lawsuit has been thrown their way, shaking up any stability folks thought they had. Levi & Korsinsky, LLP laid down the gauntlet on behalf of the shareholders hoodwinked by...

Continue Reading
Real Estate Decisions in Hospitality: Buy or Lease?

Updated Category News Views 45

Venturing into Hospitality Real Estate If you're in the hospitality game, the question of whether to buy or to lease your property can loom like a shadow or shine like an opportunity. The latest episode of the Owner's Edge Podcast by Bielat Santore & Company dives into this headfirst, armed with over 45 years of brokering experience in hospitality transactions. They don't...

Continue Reading
Shipping Stocks Rise Amid Tight Global Tanker Market

Updated Category News Views 93

Global Tanker Market Challenges Drive Earnings The energy shipping scene's got some heat this quarter, my friends. With crude oil prices getting a decent lift today, some energy shipping players are riding that wave to pretty stellar quarterly results. For those in the know, the global tanker market's choking a bit, making for tight conditions. And when the screws...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Weigh In: The Current Landscape for Riot Platforms

Updated Category News Views 156

Investors Assess the Options Market for Riot Platforms In today’s trading environment, investors have embraced a pessimistic outlook on Riot Platforms (NASDAQ: RIOT). This comes as no surprise given the substantial movements detected in the options market, indicating that something notable might be on the horizon for Riot. The notable activity is significant, showcasing...

Continue Reading
Herantis Pharma's HER-096 Achieves Milestone in Parkinson's Study

Updated Category News Views 255

Herantis Pharma Celebrates Positive Outcomes in Parkinson’s Trial Herantis Pharma has made substantial strides in its quest to develop effective therapies for those living with Parkinson’s disease. The company recently shared exciting topline results from its Phase 1b trial conducted with HER-096, a promising candidate designed to tackle the challenges of this...

Continue Reading
Beezie Unleashes New Innovations in Collectibles Resale Market

Updated Category News Views 293

Beezie Redefines the Collectibles Resale Game In an exciting development within the collectibles market, Beezie is pioneering new approaches to how resellers manage and sell high-value items like trading cards, sneakers, and memorabilia. With its innovative platform, Beezie has introduced gamification and secure vaulting, setting a new standard in the industry....

Continue Reading
Investigation into agilon health, inc.: Your Rights As an Investor

Updated Category News Views 172

Investigating Potential Claims for agilon health, inc. Investors In recent developments, shareholders of agilon health, inc. (NYSE: AGL) find themselves under scrutiny due to potentially misleading information that may have impacted their investments. The Rosen Law Firm, a respected global investor rights legal firm, is actively investigating these possible securities...

Continue Reading
Crédit Agricole S.A. Announces New Share Buyback Initiative

Updated Category News Views 265

Crédit Agricole S.A. Announces New Share Buyback Initiative Crédit Agricole S.A. is set to launch an exciting new chapter in its financial journey. The company has received all necessary supervisory approvals to commence a share repurchase program targeting up to 22,886,191 ordinary shares. This initiative is not only a strategic maneuver but also reflects the...

Continue Reading